Literature DB >> 21347749

Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.

Alan Yancovitch1, Dov Hershkovitz, Margareta Indelman, Peter Galloway, Margo Whiteford, Eli Sprecher, Esra Kılıç.   

Abstract

Hyperphosphatemic familial tumoral calcinosis (HFTC) is known to be caused by mutations in at least three genes: FGF23, GALNT3 and KL. Two families with two affected members suffering from HFTC were scrutinized for mutations in these candidate genes. We identified in both families homozygous missense mutations affecting highly conserved amino acids in GALNT3. One of the mutations is a novel mutation, whereas the second mutation was reported before in a compound heterozygous state. Our data expand the spectrum of known mutations in GALNT3 and contribute to a better understanding of the phenotypic manifestations of mutations in this gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21347749     DOI: 10.1007/s00774-011-0260-1

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  25 in total

Review 1.  Fibroblast growth factor 23: roles in health and disease.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Am Soc Nephrol       Date:  2005-07-20       Impact factor: 10.121

2.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.

Authors:  Shoji Ichikawa; Kenneth W Lyles; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

3.  Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis.

Authors:  Anna Maria Barbieri; Marcello Filopanti; Guido Bua; Paolo Beck-Peccoz
Journal:  J Hum Genet       Date:  2007-03-10       Impact factor: 3.172

4.  Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.

Authors:  Shoji Ichikawa; Vincent Guigonis; Erik A Imel; Mélanie Courouble; Sophie Heissat; John D Henley; Andrea H Sorenson; Barbara Petit; Anne Lienhardt; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

5.  The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.

Authors:  Holly J Garringer; Corinne Fisher; Tobias E Larsson; Siobhan I Davis; Daniel L Koller; Michael J Cullen; Mohamad S Draman; Niamh Conlon; Alka Jain; Neal S Fedarko; Bhaskar Dasgupta; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

6.  Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis.

Authors:  R E Slavin; J Wen; D Kumar; E B Evans
Journal:  Am J Surg Pathol       Date:  1993-08       Impact factor: 6.394

7.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.

Authors:  Orit Topaz; Daniel L Shurman; Reuven Bergman; Margarita Indelman; Paulina Ratajczak; Mordechai Mizrachi; Ziad Khamaysi; Doron Behar; Dan Petronius; Vered Friedman; Israel Zelikovic; Sharon Raimer; Arieh Metzker; Gabriele Richard; Eli Sprecher
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

8.  Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.

Authors:  Polina Specktor; John G Cooper; Margarita Indelman; Eli Sprecher
Journal:  J Hum Genet       Date:  2006-03-10       Impact factor: 3.172

9.  A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome.

Authors:  Hannes Olauson; Tijana Krajisnik; Charlotta Larsson; Bengt Lindberg; Tobias E Larsson
Journal:  Eur J Endocrinol       Date:  2008-03-05       Impact factor: 6.664

10.  Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome.

Authors:  Faysal Gok; Ilana Chefetz; Margarita Indelman; Murat Kocaoglu; Eli Sprecher
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more
  15 in total

Review 1.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

2.  Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.

Authors:  Mary Scott Ramnitz; Pravitt Gourh; Raphaela Goldbach-Mansky; Felasfa Wodajo; Shoji Ichikawa; Michael J Econs; Kenneth E White; Alfredo Molinolo; Marcus Y Chen; Theo Heller; Jaydira Del Rivero; Patricia Seo-Mayer; Bita Arabshahi; Malaka B Jackson; Sarah Hatab; Edward McCarthy; Lori C Guthrie; Beth A Brillante; Rachel I Gafni; Michael T Collins
Journal:  J Bone Miner Res       Date:  2016-09-20       Impact factor: 6.741

3.  Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.

Authors:  Q-Y Zuo; X Cao; B-Y Liu; D Yan; Z Xin; X-H Niu; C Li; W Deng; Z-Y Dong; J-K Yang
Journal:  J Endocrinol Invest       Date:  2019-09-18       Impact factor: 4.256

Review 4.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

Review 5.  A unified model for bone-renal mineral and energy metabolism.

Authors:  Peter S Rowe
Journal:  Curr Opin Pharmacol       Date:  2015-04-13       Impact factor: 5.547

Review 6.  Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.

Authors:  Lisal J Folsom; Erik A Imel
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 7.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 8.  Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.

Authors:  Nobuaki Ito; Seiji Fukumoto
Journal:  Calcif Tissue Int       Date:  2020-01-22       Impact factor: 4.333

Review 9.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Authors:  Daniel Edmonston; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2019-09-13       Impact factor: 28.314

10.  A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.

Authors:  Christopher T Esapa; Rosie A Head; Jeshmi Jeyabalan; Holly Evans; Tertius A Hough; Michael T Cheeseman; Eugene G McNally; Andrew J Carr; Gethin P Thomas; Matthew A Brown; Peter I Croucher; Steve D M Brown; Roger D Cox; Rajesh V Thakker
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.